Abstract illustration of chromosomes 8 and 17 intertwining, symbolizing the t(8;17) translocation in leukemia.

Decoding Leukemia: Understanding t(8;17) Translocation and Its Implications

Samir D’Costa monogram
Samir D’Costa in Health & Wellness November 2026 • 4 min read.

"Explore the complexities of the t(8;17)(p12;q25) chromosomal translocation in leukemia, its clinical significance, and potential therapeutic avenues."


Leukemia, a cancer of the blood and bone marrow, manifests in various forms, each with distinct genetic and molecular characteristics. Among these, chromosomal translocations—where parts of chromosomes break and reattach to other chromosomes—play a significant role in disease development and progression. The t(8;17)(p12;q25) translocation is one such genetic anomaly, although relatively rare, found in specific types of leukemia.

This particular translocation involves the exchange of genetic material between chromosome 8 and chromosome 17 at specific locations denoted as p12 (on the short arm of chromosome 8) and q25 (on the long arm of chromosome 17). Understanding the mechanisms and consequences of this translocation is crucial for refining diagnostic approaches and exploring targeted treatment strategies for affected individuals.

The following article provides an overview of the t(8;17) translocation, its association with Fibroblast Growth Factor Receptor 1 (FGFR1), clinical presentations, and implications for patients diagnosed with this rare subtype of leukemia.

AI Search Multiple angles on this topic

Source Limitations

The supplied sources do not provide statistics about leukemia or t(8;17) translocation. One source defines “T” as the twentieth letter of the Latin alphabet. Another reports that AT&T trades under the ticker symbol “T,” had a market capitalization of $186.83 billion, ranked 37th on the 2025 Fortune 500, and reported $125.6 billion in revenue last year.

Unrelated Financial Sources

The supplied sources discuss financial information rather than leukemia diagnosis or treatment. Yahoo Finance describes its page as providing AT&T Inc. stock quotes, history, news, and related information. Google Finance likewise describes its AT&T page as providing real-time stock quotes, news, financial details, and analytics, so these sources cannot establish accepted medical methods or their limitations.

Historical Context

No source material was supplied for this subsection. A reliable historical account of t(8;17) translocation would require evidence describing relevant discoveries, milestones, and dates. Those details cannot be established from the provided material.

What is t(8;17)(p12;q25) Translocation?

Abstract illustration of chromosomes 8 and 17 intertwining, symbolizing the t(8;17) translocation in leukemia.

Chromosomal translocations occur when chromosomes break and the fragments reattach in an abnormal configuration. In the case of t(8;17)(p12;q25), a piece of chromosome 8 and a piece of chromosome 17 switch places. The notation 't' indicates a translocation, while '(8;17)' specifies the chromosomes involved. '(p12)' refers to the location on the short arm (p) of chromosome 8, and '(q25)' indicates the location on the long arm (q) of chromosome 17.

This translocation is significant because it often involves the Fibroblast Growth Factor Receptor 1 (FGFR1) gene, located at 8p12. FGFR1 is a receptor tyrosine kinase that plays a critical role in cell growth, differentiation, and angiogenesis (the formation of new blood vessels). When this gene is disrupted or inappropriately activated due to the translocation, it can lead to uncontrolled cell proliferation and the development of leukemia.

  • Gene Disruption: The translocation can disrupt the normal function of genes at the breakpoints, especially FGFR1.
  • Uncontrolled Proliferation: Dysregulation of FGFR1 leads to excessive cell growth and division.
  • Leukemia Development: The abnormal proliferation of cells contributes to the onset and progression of leukemia.
AI Search Multiple angles on this topic

Research Evidence

No source material was supplied for this subsection. Accordingly, no specific recent study, review, finding, or research trend about t(8;17) translocation can be reported here. Further interpretation would require appropriately focused medical sources.

Evidence Gaps

No source material was supplied for this subsection. The available information therefore does not support identifying competing interpretations, failed approaches, or limitations in research on t(8;17) translocation. Any such discussion would be speculative.

Comparison Not Established

No source material was supplied for this subsection. Comparisons involving t(8;17) translocation, other chromosomal abnormalities, diagnoses, or treatments cannot be made responsibly from the information provided. Focused comparative medical evidence would be needed.

The t(8;17) translocation is relatively rare, and it's often associated with specific types of hematological malignancies, including myeloproliferative neoplasms and, in some cases, acute leukemias. Understanding the clinical context and specific features of the translocation is essential for accurate diagnosis and tailored treatment.

Future Directions and Research

Continued research into the t(8;17) translocation and its effects on FGFR1 signaling pathways is essential for developing more effective, targeted therapies. Clinical trials and studies focusing on patients with this specific translocation can provide valuable insights into optimal treatment strategies and long-term outcomes. As genetic sequencing and diagnostic technologies advance, a more comprehensive understanding of the molecular landscape in these leukemias will pave the way for personalized medicine approaches, improving patient outcomes and quality of life.

AI Search Multiple angles on this topic

Local Service Context

The supplied source concerns T-Mobile stores and wireless services, not leukemia or t(8;17) translocation. It states that people can find nearby T-Mobile stores for cell phones, wireless plans, and local services. It also mentions expert in-person setup and the option to switch online or in-store, but provides no medical expert commentary.

Future Evidence Needed

No source material was supplied for this subsection. Specific claims about future research, emerging diagnostics, or treatment frontiers for t(8;17) translocation therefore cannot be verified. A cautious outlook would require current, disease-specific research sources.

Contextual Evidence Gap

No source material was supplied for this subsection. The provided information does not support conclusions about healthcare systems, access, policy, or broader challenges affecting people with t(8;17) translocation. Those issues should be addressed only with relevant evidence.

Patient Impact

No source material was supplied for this subsection. Patient experiences, quality-of-life effects, and real-world consequences of t(8;17) translocation cannot be described accurately from the available information. Disease-specific patient or clinical sources would be necessary.

How FGFR1 rearrangement reports compare

A review describes at least 15 chromosome translocations associated with the syndrome and identifies recurring features: breakpoints in FGFR1 intron 8, upstream of its kinase domain, and a dimerization or oligomerization domain in the partner gene. This broader pattern places the MYO18A–FGFR1 fusion among multiple reported rearrangements, not as the sole form.[1]

Clinical outcome figures in the cited sources use different populations and endpoints: one early series reported remission after intensive chemotherapy, while another reported survival from diagnosis across all cases. These figures are not directly interchangeable, and neither establishes an outcome specifically for the MYO18A–FGFR1 fusion.[1] [2]

What remains unclear about t(8;17)

  • How often does the reported three-way MYO18A–FGFR1 rearrangement occur among FGFR1-associated cases, given that the breakpoint characterization was partial?[3]
  • How much do outcomes vary by fusion partner, when different FGFR1 fusions are associated with subtly different phenotypes and treatment reports often involve individual cases?[1] [3]

Terms used in FGFR1 rearrangement reports

Three-way translocation
A rearrangement involving breaks across three chromosome locations.[3]
Dimerization/oligomerization domain
A region of a partner gene associated with dimerization or oligomerization.[1]

Sources

  1. Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment (pmc.ncbi.nlm.nih.gov)
  2. Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement. (www.tandfonline.com)
  3. The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. (pubmed.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.4267/2042/44541, Alternate LINK

Title: T(8;17)(P12;Q25)

Subject: Cancer Research

Journal: Atlas of Genetics and Cytogenetics in Oncology and Haematology

Publisher: INIST-CNRS

Authors: Jl Huret

Published: 2011-11-01

Everything You Need To Know

1

What is the t(8;17)(p12;q25) translocation, and how does it relate to leukemia?

The t(8;17)(p12;q25) translocation is a genetic anomaly where parts of chromosome 8 and chromosome 17 switch places. Specifically, a piece from the short arm (p12) of chromosome 8 exchanges with a piece from the long arm (q25) of chromosome 17. This translocation is linked to leukemia because it often involves the Fibroblast Growth Factor Receptor 1 (FGFR1) gene, located at 8p12. This disruption can lead to uncontrolled cell proliferation and, consequently, leukemia development.

2

What is the role of FGFR1 in the context of the t(8;17) translocation?

FGFR1, a receptor tyrosine kinase, is critically involved in cell growth, differentiation, and angiogenesis. In the t(8;17) translocation, FGFR1 can be disrupted or inappropriately activated. This dysregulation of FGFR1 leads to excessive cell growth and division, a hallmark of leukemia. The translocation can cause the FGFR1 gene to become dysregulated, leading to uncontrolled cell proliferation that contributes to the onset and progression of leukemia.

3

What are the clinical implications of the t(8;17) translocation in leukemia?

The t(8;17) translocation is associated with specific types of hematological malignancies, including myeloproliferative neoplasms and, in some cases, acute leukemias. Understanding the clinical context and the specific features of the translocation is essential for accurate diagnosis. This knowledge helps guide treatment strategies tailored to the individual patient, potentially improving outcomes and quality of life. The presence of this translocation influences disease presentation and treatment approaches.

4

How does the t(8;17) translocation lead to leukemia development, specifically?

The t(8;17) translocation initiates leukemia development through several mechanisms. Firstly, the translocation can disrupt the normal function of genes at the breakpoints, particularly FGFR1. Secondly, this disruption can lead to uncontrolled cell proliferation as FGFR1 becomes dysregulated, causing excessive cell growth and division. Ultimately, the abnormal proliferation of cells due to the translocation contributes to the onset and progression of leukemia. The precise effects depend on the specific genes involved and the cellular context.

5

What are the future directions in research and treatment for leukemia patients with the t(8;17) translocation?

Future research directions include continued investigation into the t(8;17) translocation and its effects on FGFR1 signaling pathways to develop more effective, targeted therapies. Clinical trials focusing on patients with this specific translocation are crucial for understanding optimal treatment strategies and long-term outcomes. As genetic sequencing and diagnostic technologies advance, a more comprehensive understanding of the molecular landscape in these leukemias will pave the way for personalized medicine approaches, improving patient outcomes and quality of life.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.